Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2012

Sep 25, 2012

32418_dirs_2012-09-25_224e3a3b-9b25-4e91-8f12-2b20fe5e5897.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-08-28

Reporting Person: Dunkerley Hugh D P (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-08-28 Employee Stock Options (right to buy) $0.64 A 75000 Acquired 2022-08-28 Common Stock (75000) Direct

Footnotes

F1: Options vest 1/12th every month for 12 months and will be fully vested as of August 28, 2013.